PHASE IIA: Trial of a Novel Ondansetron Formulation (OND-PR002) and Immediate-Release Methylphenidate (Ritalin®)(OND003IND)
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Ashwin A Patkar, MD
Psychiatry and Behavioral Sciences
Principal Investigator - Robert J Noveck, MD,PhD
Duke Clinical Research Unit
Principal Investigator - Tong Lee, MD, PhD
Associate Professor Psychiatry and Behavorial Science, Duke University Medical Center
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
3 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Duke Addictions Clinic
Durham, North Carolina, United States
- Duke Clinical Research Unit
Durham, North Carolina, United States
- Southlight
Raleigh, North Carolina, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 31 Aug 2011
- Primary completion
- 31 May 2013
- Completion
- 31 May 2013
- Last update posted
- 7 Oct 2014
- Registered enrollment
- 30
- Registry id
- NCT01377662
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.